Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Radiother Oncol. 2022 Mar;168:61-68. doi: 10.1016/j.radonc.2022.01.026. Epub 2022 Jan 29.
In this study, we aimed to establish and validate an integrated prognostic model for locally recurrent nasopharyngeal carcinoma (lrNPC) patients, and evaluate the benefit of re-radiotherapy (re-RT) in patients with different risk levels.
In total, 531 patients with lrNPC were retrospectively reviewed in this study, including 271 patients from 2006 to 2012 as the training cohort and 260 patients from 2013 to 2016 as the validation cohort. Overall survival (OS) was the primary endpoint. Multivariate analysis was performed to select the significant prognostic factors (P < 0.05). A prognostic model for OS was derived by recursive partitioning analysis (RPA) combining independent predictors using the algorithm of optimized binary partition.
Three independent prognostic factors (age, relapsed T [rT] stage, and Epstein-Barr virus [EBV] DNA) were identified from multivariate analysis. Five prognostic groups were derived from an RPA model that combined rT stage and EBV DNA. After further pair-wise comparisons of survival outcome in each group, three risk groups were generated. We investigated the role of re-RT in different risk groups, and found that re-RT could benefit patients in the low (P < 0.001) and intermediate-risk subgroups (P = 0.017), while no association between re-RT and survival benefit was found in the high-risk subgroup (P = 0.328). The results of risk stratification and re-RT efficacy were verified in the validation cohort.
Age, rT stage and EBV DNA were identified as independent predictors for lrNPC. We established an integrated RPA-based prognostic model for OS incorporating rT stage and EBV DNA, which could guide individual treatment for lrNPC.
本研究旨在建立并验证局部复发鼻咽癌(lrNPC)患者的综合预后模型,并评估不同风险水平患者再次放疗(re-RT)的获益。
本研究回顾性分析了 531 例 lrNPC 患者,其中 271 例来自 2006 年至 2012 年的训练队列,260 例来自 2013 年至 2016 年的验证队列。总生存(OS)为主要终点。多变量分析用于选择显著的预后因素(P<0.05)。使用优化二分划分算法,通过递归分区分析(RPA)将独立预测因子结合起来,得出 OS 的预后模型。
多变量分析确定了 3 个独立的预后因素(年龄、复发 T 期[rT 期]和 EBV DNA)。RPA 模型将 rT 期和 EBV DNA 结合起来,得出 5 个预后组。进一步对每组生存结果进行两两比较,得出 3 个风险组。我们研究了 re-RT 在不同风险组中的作用,发现 re-RT 可使低危(P<0.001)和中危组(P=0.017)患者获益,而高危组中 re-RT 与生存获益之间无关联(P=0.328)。在验证队列中验证了风险分层和 re-RT 疗效的结果。
年龄、rT 期和 EBV DNA 被确定为 lrNPC 的独立预测因素。我们建立了一个基于 RPA 的综合 OS 预后模型,纳入了 rT 期和 EBV DNA,可指导 lrNPC 的个体化治疗。